Disease on EC 1.14.11.68 - [histone H3]-trimethyl-L-lysine27 demethylase
Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Acrocephalosyndactylia
Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre-Chotzen syndrome.
Adenocarcinoma
Blocking the road to de-differentiation: HNF1A/KDM6A complex safeguards epithelial integrity in pancreatic cancer.
Adenocarcinoma
HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
Adenocarcinoma
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Adenocarcinoma
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Adenocarcinoma
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
Alagille Syndrome
Cystic biliary atresia with paucity of bile ducts and gene mutation in KDM6A: a case report.
Apnea
A novel mouse model of obstructive sleep apnea by bulking agent-induced tongue enlargement results in left ventricular contractile dysfunction.
Arthritis
LncRNA H19 regulates macrophage polarization and promotes Freund's complete adjuvant-induced arthritis by upregulating KDM6A.
Autoimmune Diseases
Demethylase Kdm6a epigenetically promotes IL-6 and IFN-? production in macrophages.
Autoimmune Diseases
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
Biliary Atresia
Cystic biliary atresia with paucity of bile ducts and gene mutation in KDM6A: a case report.
Breast Neoplasms
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.
Breast Neoplasms
Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness.
Breast Neoplasms
Inhibition of Histone Demethylases LSD1 and UTX Regulates ER? Signaling in Breast Cancer.
Breast Neoplasms
The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition.
Carcinogenesis
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Carcinogenesis
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Carcinogenesis
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Carcinogenesis
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Carcinoma
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Carcinoma
Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma.
Carcinoma
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma
KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress.
Carcinoma
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines.
Carcinoma
Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Carcinoma
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Carcinoma
System Review about Function Role of ESCC Driver Gene KDM6A by Network Biology Approach.
Carcinoma
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma, Adenoid Cystic
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma, Hepatocellular
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Carcinoma, Renal Cell
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Carcinoma, Squamous Cell
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chordoma
Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death.
Cleft Palate
Haploinsufficiency of KDM6A is associated with severe psychomotor retardation, global growth restriction, seizures and cleft palate.
Coloboma
A case of exudative vitreoretinopathy and chorioretinal coloboma associated with microcephaly in a female with contiguous Xp11.3-11.4 deletion.
Colonic Neoplasms
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Colorectal Neoplasms
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Congenital Hyperinsulinism
Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Identification of KMT2D and KDM6A variants by targeted sequencing from patients with Kabuki syndrome and other congenital disorders.
Craniosynostoses
Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre-Chotzen syndrome.
Diabetic Nephropathies
A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction.
Diabetic Nephropathies
hsa-miR-199b-3p Prevents the Epithelial-Mesenchymal Transition and Dysfunction of the Renal Tubule by Regulating E-cadherin through Targeting KDM6A in Diabetic Nephropathy.
Encephalomyelitis
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
Esophageal Squamous Cell Carcinoma
System Review about Function Role of ESCC Driver Gene KDM6A by Network Biology Approach.
Gastrointestinal Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Genetic Diseases, Inborn
Ophthalmic manifestations in Kabuki (make-up) syndrome: A single-center pediatric cohort and systematic review of the literature.
Graft vs Host Disease
Genetic Profile and Microsatellite Instability in a Case of Secondary Esophageal Squamous Cell Carcinoma 12 Years After Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.
Hearing Loss, Sensorineural
Clinical update on sensorineural hearing loss in Turner syndrome and the X-chromosome.
Hydrocephalus
Novel KDM6A splice-site mutation in kabuki syndrome with congenital hydrocephalus: a case report.
Hyperinsulinism
Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency.
Hypertrichosis
Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2).
Hypogonadism
Peripheral Precocious Puberty of Ovarian Origin in a Series of 18 Girls: Exome Study Finds Variants in Genes Responsible for Hypogonadotropic Hypogonadism.
Infections
[Treatment and genetic analysis of a child with Kabuki syndrome type 2 and secondary pulmonary infection due to a de novo variant of KDM6A gene].
Influenza, Human
Long-term exposure to PM2.5 lowers influenza virus resistance via down-regulating pulmonary macrophage Kdm6a and mediates histones modification in IL-6 and IFN-? promoter regions.
Leukemia
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
Leukemia, Myeloid, Acute
Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
Leukemia, Myeloid, Acute
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Leukemia, Myelomonocytic, Chronic
Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.
Liver Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Lung Neoplasms
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Lung Neoplasms
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Lung Neoplasms
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Lymphoma
Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Medulloblastoma
OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels.
Melanoma
Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.
Mesothelioma, Malignant
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.
Metabolic Syndrome
Kdm6a suppresses the alternative activation of macrophages and impairs energy expenditure in obesity.
Microcephaly
A case of exudative vitreoretinopathy and chorioretinal coloboma associated with microcephaly in a female with contiguous Xp11.3-11.4 deletion.
Neoplasm Metastasis
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Neoplasm Metastasis
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
Neoplasms
A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors.
Neoplasms
A Diffusion-like Process Accommodates New Crypts During Clonal Expansion in Human Colonic Epithelium.
Neoplasms
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.
Neoplasms
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Neoplasms
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Neoplasms
Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness.
Neoplasms
Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.
Neoplasms
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Neoplasms
Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer.
Neoplasms
Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
Neoplasms
dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes.
Neoplasms
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Neoplasms
Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
Neoplasms
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Neoplasms
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Neoplasms
Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Neoplasms
Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma.
Neoplasms
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Neoplasms
Genetic profiling of patients with adenoid cystic carcinoma of the Bartholin's glands reveals potential new routes for targeted therapies: a case report.
Neoplasms
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
Neoplasms
Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer.
Neoplasms
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
Neoplasms
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Neoplasms
Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt/?-catenin signaling.
Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Neoplasms
Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin.
Neoplasms
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Neoplasms
Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction.
Neoplasms
KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
Neoplasms
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Neoplasms
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines.
Neoplasms
Local sequence assembly reveals a high-resolution profile of somatic structural variations in 97 cancer genomes.
Neoplasms
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Neoplasms
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Neoplasms
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Neoplasms
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Neoplasms
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Neoplasms
Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites.
Neoplasms
Puerarin 6?-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.
Neoplasms
Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
Neoplasms
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Neoplasms
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma.
Neoplasms
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Neoplasms
Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.
Neoplasms
Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
Neoplasms
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Neoplasms
The evolution of bladder cancer genomics: What have we learned and how can we use it?
Neoplasms
The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition.
Neoplasms
Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.
Neoplasms
UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.
Neoplasms
X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism.
Neuroinflammatory Diseases
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
Obesity
Kdm6a suppresses the alternative activation of macrophages and impairs energy expenditure in obesity.
Obesity
Restoration of H3k27me3 Modification Epigenetically Silences Cry1 Expression and Sensitizes Leptin Signaling to Reduce Obesity-Related Properties.
Osteoarthritis
KDM6A promotes chondrogenic differentiation of periodontal ligament stem cells by demethylation of SOX9.
Osteoarthritis
The therapeutic effect of bone marrow-derived mesenchymal stem cells on osteoarthritis is improved by the activation of the KDM6A/SOX9 signaling pathway caused by exposure to hypoxia.
Pancreatic Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Pancreatic Neoplasms
HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
Pancreatic Neoplasms
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Pancreatic Neoplasms
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
Proteinuria
A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction.
Pulmonary Disease, Chronic Obstructive
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Seizures
Haploinsufficiency of KDM6A is associated with severe psychomotor retardation, global growth restriction, seizures and cleft palate.
Spinal Cord Injuries
MicroRNA-145-Mediated KDM6A Downregulation Enhances Neural Repair after Spinal Cord Injury via the NOTCH2/Abcb1a Axis.
Squamous Cell Carcinoma of Head and Neck
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Stomach Neoplasms
Expression pattern of histone lysine-specific demethylase 6B in gastric cancer.
Stomach Neoplasms
Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
Stomach Neoplasms
[KDM6A mutation and expression in gastric cancer are associated with prognosis].
Stroke
X chromosome escapee genes are involved in ischemic sexual dimorphism through epigenetic modification of inflammatory signals.
Tics
Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer.
Triple Negative Breast Neoplasms
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Triple Negative Breast Neoplasms
The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition.
Turner Syndrome
Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency.
Turner Syndrome
Mutation Update for Kabuki Syndrome Genes KMT2D and KDM6A and Further Delineation of X-Linked Kabuki Syndrome Subtype 2.
Urinary Bladder Neoplasms
A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors.
Urinary Bladder Neoplasms
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Urinary Bladder Neoplasms
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Urinary Bladder Neoplasms
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
Urinary Bladder Neoplasms
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction.
Urinary Bladder Neoplasms
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
Urinary Bladder Neoplasms
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Urinary Bladder Neoplasms
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
Urinary Bladder Neoplasms
Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
Uterine Cervical Neoplasms
KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress.
[histone h3]-trimethyl-l-lysine27 demethylase deficiency
HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
[histone h3]-trimethyl-l-lysine27 demethylase deficiency
Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction.
[histone h3]-trimethyl-l-lysine27 demethylase deficiency
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
[histone h3]-trimethyl-l-lysine27 demethylase deficiency
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
html completed